AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6285814 — intervention group
Group type: COMPARATOR
Intervention: Miconazole after fasting (250 mg)
Number of subjects: 10
Study 30376391 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 2 of HEI‐2010 score
Number of subjects: 1220
Study 30376391 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 3 of HEI‐2010 score
Number of subjects: 1220
Study 30376391 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 of HEI‐2010 score
Number of subjects: 1220
Study 30376391 — intervention group
Group type: COMPARATOR
Intervention: Quartiles 2, 3, and 4 of HEI‐2010 score
Number of subjects: 1220
Study 28671000 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50
Study 28671000 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 50
Study 25644619 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear lens extraction by phacoemulsification
Number of subjects: 50
Study 25644619 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 50
Study 24499492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg NRL001
Number of subjects: 26
Study 24499492 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg NRL001
Number of subjects: 26
Study 24499492 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg NRL001
Number of subjects: 26
Study 24499492 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g suppository (NRL001)
Number of subjects: 26
Study 24499492 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g suppository (NRL001)
Number of subjects: 26
Study 24499492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24499492 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 (up to 15 mg)
Number of subjects: 26
Study 24499492 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001
Number of subjects: 26
Study 21791543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention to optimize pharmacological therapy
Number of subjects: 1092
Study 21791543 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1092
Study 19402341 — intervention group
Group type: COMPARATOR
Intervention: Commercial tablets (COM) 150 mg
Number of subjects: 16
Study 19402341 — intervention group
Group type: EXPERIMENTAL
Intervention: Magistral suspension (MAG) 150 mg
Number of subjects: 16
Study 19402341 — intervention group
Group type: EXPERIMENTAL
Intervention: Magistral suspension (MAG)
Number of subjects: 16
Study 19402341 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (COM and MAG)
Number of subjects: 16
Study 15081450 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy before direct infarct artery stenting
Number of subjects: 100
Study 15081450 — intervention group
Group type: COMPARATOR
Intervention: Direct infarct artery stenting alone (placebo group)
Number of subjects: 100
Study 11845943 — intervention group
Group type: EXPERIMENTAL
Intervention: adapalene gel 0.1%
Number of subjects: 168
Study 11845943 — intervention group
Group type: COMPARATOR
Intervention: tretinoin microsphere gel 0.1%
Number of subjects: 168
Study 9576145 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic T-cell lines
Number of subjects: 0
Study 9576145 — intervention group
Group type: COMPARATOR
Intervention: Nonatopic T-cell lines
Number of subjects: 0
Study 7820040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 90
Study 7820040 — intervention group
Group type: COMPARATOR
Intervention: Alpha interferon (aIF)
Number of subjects: 90
Study 3289524 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 12
Study 3289524 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 12
Study 29848361 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat XR 40 mg
Number of subjects: 189
Study 29848361 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat IR 40 mg
Number of subjects: 189
Study 29848361 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat IR 80 mg
Number of subjects: 189
Study 29848361 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat XR 80 mg
Number of subjects: 189
Study 29848361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 28196003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 5 mg
Number of subjects: 20
Study 28196003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 25 mg
Number of subjects: 20
Study 28196003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 50 mg
Number of subjects: 20
Study 28196003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 100 mg
Number of subjects: 20
Study 28196003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25717011 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Living (DAL) residents with dementia
Number of subjects: 609
Study 25717011 — intervention group
Group type: COMPARATOR
Intervention: Long-Term Care (LTC) residents with dementia
Number of subjects: 609
Study 24617242 — intervention group
Group type: COMPARATOR
Intervention: Routine drug anesthesia (group A)
Number of subjects: 124
Study 24617242 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian point 2 Hz (group B)
Number of subjects: 124
Study 24617242 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian point 2 Hz/100 Hz (group C)
Number of subjects: 124
Study 24617242 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian point 100 Hz (group D)
Number of subjects: 124
Study 24617242 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electric stimulation 2 Hz/100 Hz (group E)
Number of subjects: 124
Study 21266337 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 47
Study 21266337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21266337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 47
Study 17375114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy parenteral nutrition without amino acids
Number of subjects: 0
Study 17375114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy parenteral nutrition containing amino acids (two types)
Number of subjects: 0
Study 17375114 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete parenteral nutrition
Number of subjects: 0
Study 16533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance narrow-band UVB therapy for 2 months
Number of subjects: 50
Study 16533223 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 50
Study 16533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance narrow-band UVB therapy for plaque-type psoriasis
Number of subjects: 50
Study 16533223 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy for plaque-type psoriasis
Number of subjects: 50
Study 12933413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (Group K)
Number of subjects: 93
Study 12933413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group M)
Number of subjects: 93
Study 10643851 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 million units/m2 body surface area of recombinant interferon alpha 2b (Group I)
Number of subjects: 30
Study 10643851 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 million units/m2 body surface area of recombinant interferon alpha 2b (Group II)
Number of subjects: 30
Study 8880107 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 micrograms b.d.
Number of subjects: 190
Study 8880107 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol 400 micrograms q.d.s.
Number of subjects: 190
Study 1325319 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (2 pmol min‐1 kg‐1)
Number of subjects: 6
Study 1325319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 150 mmol/l NaCl)
Number of subjects: 6
Study 6380466 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular drops of 0.25% clonidine
Number of subjects: 16
Study 6380466 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular drops of 0.50% clonidine
Number of subjects: 16
Study 6380466 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidrops of 0.25% clonidine
Number of subjects: 16
Study 6380466 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidrops of 0.50% clonidine
Number of subjects: 16
Study 6380466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0% clonidine)
Number of subjects: 16
Study 29912429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L/min for 6-12 hours
Number of subjects: 2807
Study 29912429 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 2807
Study 29912429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 2807
Study 26159803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 80
Study 26159803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24799602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels (<32 ng/mL)
Number of subjects: 411
Study 24799602 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline low 25(OH)D
Number of subjects: 411
Study 24799602 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO stage 3/4 disease or death within 96 weeks of cART initiation
Number of subjects: 411
Study 24799602 — intervention group
Group type: EXPERIMENTAL
Intervention: Virologic failure
Number of subjects: 411
Study 24799602 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic failure
Number of subjects: 411
Study 23306096 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8mg/day) - DOX-fast group
Number of subjects: 35
Study 23306096 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8mg/day) - DOX-slow group
Number of subjects: 35
Study 23306096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 20424590 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 1 Hz rTMS
Number of subjects: 52
Study 20424590 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 52
Study 17922525 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 8214
Study 17922525 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 8214
Study 16824243 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural infusion of 0.2% ropivacaine (group EPI, n = 21)
Number of subjects: 42
Study 16824243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral infusion of 0.2% ropivacaine (group PVB, n = 21)
Number of subjects: 42
Study 12796858 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-reinforced nonnutritive sucking intervention (n = 16)
Number of subjects: 32
Study 12796858 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group (n = 16)
Number of subjects: 32
Study 10993126 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 778
Study 10993126 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 778
Study 9191873 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (picibanil) administered ID twice weekly for 3 months at dosages ranging from 1 KE to 20 KE
Number of subjects: 48
Study 9191873 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (picibanil) administered ID twice weekly for 3 months
Number of subjects: 48
Study 7693476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrizym 22 (double strength)
Number of subjects: 25
Study 7693476 — intervention group
Group type: COMPARATOR
Intervention: Nutrizym GR (standard preparation)
Number of subjects: 25
Study 3963089 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine mesylate (Parlodel)
Number of subjects: 75
Study 3963089 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 28639554 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in group A
Number of subjects: 23
Study 28639554 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels in group A
Number of subjects: 23
Study 28639554 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in patients with low-frequency hearing loss
Number of subjects: 23
Study 28639554 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis of procalcitonin values
Number of subjects: 23
Study 28639554 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin levels in group B
Number of subjects: 23
Study 28639554 — intervention group
Group type: COMPARATOR
Intervention: hs-CRP levels in group B
Number of subjects: 23
Study 26509361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (median dose = 800 mcg)
Number of subjects: 130
Study 26509361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Number of subjects: 130
Study 25370587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg) plus standard care
Number of subjects: 3035
Study 25370587 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 3035
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine/70% isopropyl alcohol
Number of subjects: 2400
Study 23782845 — intervention group
Group type: COMPARATOR
Intervention: 5% povidone iodine/69% ethanol
Number of subjects: 2400
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced skin cleaning prior to disinfection
Number of subjects: 2400
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of skin colonization at catheter insertion site
Number of subjects: 2400
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of catheter colonization and catheter-related bacteremia
Number of subjects: 2400
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous tolerance
Number of subjects: 2400
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 2400
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 2400
Study 23782845 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs
Number of subjects: 2400
Study 21118175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of bisoprolol and ivabradine (mean dose 10.7±3.1 mg/day)
Number of subjects: 50
Study 21118175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of bisoprolol and ivabradine
Number of subjects: 50
Study 21118175 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol alone
Number of subjects: 50
Study 18375472 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial epicardial radiofrequency (RF) ablation
Number of subjects: 39
Study 18375472 — intervention group
Group type: COMPARATOR
Intervention: No ablation
Number of subjects: 39
Study 16603801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative sums (cusums) method using interval blood pressure values
Number of subjects: 0
Study 16603801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative sums (cusums) method with altered CPS time by 1 hour
Number of subjects: 0
Study 16603801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative sums (cusums) method with hourly readings
Number of subjects: 0
Study 10979639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiklid
Number of subjects: 54
Study 10979639 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 54
Study 8839318 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey items on HIV-related behaviors with anonymity
Number of subjects: 291
Study 8839318 — intervention group
Group type: COMPARATOR
Intervention: Survey items on HIV-related behaviors without anonymity
Number of subjects: 291
Study 1442344 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid regimen A (7 weeks duration)
Number of subjects: 54
Study 1442344 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid regimen B (15 weeks duration)
Number of subjects: 54
Study 3982468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (4000 U per minute, total of 286,000 +/- 77,800 U over 72 +/- 24 minutes)
Number of subjects: 250
Study 3982468 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 250
Study 3982468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 250
Study 3982468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase with successful reperfusion
Number of subjects: 250
Study 3982468 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial reperfusion
Number of subjects: 250
Study 3982468 — intervention group
Group type: EXPERIMENTAL
Intervention: No reperfusion
Number of subjects: 250
Study 31874985 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment cream
Number of subjects: 31
Study 31874985 — intervention group
Group type: COMPARATOR
Intervention: control cream
Number of subjects: 31
Study 31874985 — intervention group
Group type: EXPERIMENTAL
Intervention: anticipatory treatment cues
Number of subjects: 31
Study 31874985 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo responders
Number of subjects: 31
Study 29484257 — intervention group
Group type: COMPARATOR
Intervention: Cathodal HD-tDCS (1.5-mA, 20-min)
Number of subjects: 0
Study 29484257 — intervention group
Group type: COMPARATOR
Intervention: Anodal HD-tDCS (1.5-mA, 20-min)
Number of subjects: 0
Study 29484257 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 0
Study 26111957 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron (0.25, 0.75, or 2.25 mg)
Number of subjects: 221
Study 26111957 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 221
Study 26111957 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin (400 mg)
Number of subjects: 221
Study 24621778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin in combination with CSII therapy
Number of subjects: 80
Study 24621778 — intervention group
Group type: COMPARATOR
Intervention: CSII monotherapy
Number of subjects: 80
Study 22966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 723
Study 22966009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 723
Study 22966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive participants
Number of subjects: 723
Study 20451686 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐OM3 4 g/day
Number of subjects: 256
Study 20451686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 17926090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol-ethanol mixture (LEM; Group A)
Number of subjects: 13
Study 17926090 — intervention group
Group type: COMPARATOR
Intervention: Lipiodol alone (Group B)
Number of subjects: 13
Study 17926090 — intervention group
Group type: COMPARATOR
Intervention: Lipiodol and gelatin pledgets (Group C)
Number of subjects: 13
Study 19818685 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (800 mg/m2 per day, days 1-5, every 4 weeks)
Number of subjects: 704
Study 19818685 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (irinotecan 70 mg/m2 on days 1 and 15, cisplatin 80 mg/m2 on day 1, every 4 weeks)
Number of subjects: 704
Study 19818685 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (40 mg/m2 twice a day, days 1-28, every 6 weeks)
Number of subjects: 704
Study 15229770 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 1151
Study 11697841 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel at 100 mg/m2 every three weeks (with a switch to 40 mg/m2 weekly in case of severe toxicity)
Number of subjects: 27
Study 11697841 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (reinduction after progression)
Number of subjects: 27
Study 9596428 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg pseudoephedrine
Number of subjects: 150
Study 9596428 — intervention group
Group type: EXPERIMENTAL
Intervention: oxymetazoline nasal spray (0.05%)
Number of subjects: 150
Study 9596428 — intervention group
Group type: COMPARATOR
Intervention: double placebo (capsule and nasal spray)
Number of subjects: 150
Study 7869015 — intervention group
Group type: EXPERIMENTAL
Intervention: Monospecific antivenin therapy (60 ml administered intravenously at 6-hour intervals until blood coagulability is restored)
Number of subjects: 30
Study 7869015 — intervention group
Group type: EXPERIMENTAL
Intervention: Monospecific antivenin therapy
Number of subjects: 30
Study 3215145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose T3 administration (25 micrograms per day for 4 weeks)
Number of subjects: 44
Study 3215145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 31801608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder group
Number of subjects: 10
Study 31801608 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 10
Study 28796588 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CHOP (Obinutuzumab plus CHOP)
Number of subjects: 1418
Study 28796588 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (Rituximab plus CHOP)
Number of subjects: 1418
Study 28796588 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CHOP
Number of subjects: 1418
Study 28796588 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 1418
Study 26332503 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC-RC (DRE-based version 3/4)
Number of subjects: 1996
Study 26332503 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPT-RC (version 2.0)
Number of subjects: 1996
Study 26332503 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC-RC
Number of subjects: 1996
Study 26332503 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPT-RC
Number of subjects: 1996
Study 24951296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (70 mL) consumed 150 min before the first time trial
Number of subjects: 26
Study 24951296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (70 mL) consumed 75 min before the first time trial
Number of subjects: 26